2024 World Conference on Lung Cancer (WCLC) - Posters-P1.06B.16 HER3 Expression Across Genomic Subsets of NSCLC

Pdf Summary

The study investigates the expression of Human Epidermal Growth Factor Receptor 3 (HER3, also known as ERBB3) across various genomic subsets of non-small cell lung cancer (NSCLC). HER3 is a promising target for novel antibody drug conjugates, yet its expression beyond tumors with EGFR mutations remains underexplored. The study analyzed ERBB3 expression patterns in different NSCLC molecular subtypes and examined the association with survival, alongside the impact of tyrosine kinase inhibitor (TKI) exposure.<br /><br />Using next-generation sequencing of DNA and RNA, researchers assessed 52,690 NSCLC samples from Caris Life Sciences and measured ERBB3 expression in transcripts per million (TPM). Results showed that ERBB3 is frequently expressed in multiple NSCLC genomic subsets, including those harboring EGFR, HER2, and KRAS mutations, although expression levels vary significantly based on specific mutations. Notably, in EGFR mutant NSCLC, ERBB3 expression was highest in TKI-naive samples and those with exon 20 insertion mutations.<br /><br />The data revealed that high ERBB3 expression is linked to improved overall survival, supporting the role of HER3 as a therapeutic target across multiple molecular subsets of NSCLC. Patients with high ERBB3 expression showed a survival extension to 22.34 months compared to 15.69 months for those with low expression. Significant survival benefits were particularly noted in patients with common EGFR mutations and KRAS mutations.<br /><br />In conclusion, the study emphasizes the potential of targeting HER3 in NSCLC treatments, given its prevalent expression across several genetic subtypes and its association with extended patient survival, highlighting its viability as a therapeutic target.

Asset Subtitle

Brinda Gupta

Meta Tag

Speaker Brinda Gupta

Topic Metastatic NSCLC – Cytotoxic Therapy

Keywords

HER3

ERBB3

NSCLC

EGFR mutations

tyrosine kinase inhibitor

next-generation sequencing

KRAS mutations

HER2 mutations

overall survival

therapeutic target